As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Modular Devices is excited to announce the addition of David Frank as Fractional Chief Commercial Officer, reinforcing the company's commitment to strategic growth and leadership within the cleanroom ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Designed using Daiichi Sankyo's proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in ...

The rest of Plexxikon's pipeline is in early clinical or preclinical ... Pharmaphorum reached out to Daiichi Sankyo to ask for details about the fate of the programmes and Plexxikon's 60-strong ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

The agreement is one of a series of pipeline-boosting deals that MSD ... of three antibody-drug conjugate (ADC) therapies from Daiichi Sankyo for $4 billion upfront in October last year.